The 43rd Prix Galien France today recognized Genethon for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of “Medicines destined for rare diseases – cell therapy and gene therapy.”
Created in 1990 by a patient association, the AFM-Téléthon, and 90% financed by donations from the French Téléthon, Genethon is dedicated to the development of gene therapy treatments for rare diseases - from their discovery through production and through their pre- clinical and clinical development. This is the first time that a non-profit organization, created by a patient association, has received the PRIX GALIEN FRANCE.